Mitochondrial reprogramming via ATP5H loss promotes multimodal cancer therapy resistance

Kwon Ho Song, Jae Hoon Kim, Young Ho Lee, Hyun Cheol Bae, Hyo Jung Lee, Seon Rang Woo, Se Jin Oh, Kyung Mi Lee, Cassian Yee, Bo Wook Kim, Hanbyoul Cho, Eun Joo Chung, Joon Yong Chung, Stephen M. Hewitt, Tae Wook Chung, Ki Tae Ha, Young Ki Bae, Chih Ping Mao, Andrew Yang, T. C. WuTae Woo Kim

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The host immune system plays a pivotal role in the emergence of tumor cells that are refractory to multiple clinical interventions including immunotherapy, chemotherapy, and radiotherapy. Here, we examined the molecular mechanisms by which the immune system triggers cross-resistance to these interventions. By examining the biological changes in murine and tumor cells subjected to sequential rounds of in vitro or in vivo immune selection via cognate cytotoxic T lymphocytes, we found that multimodality resistance arises through a core metabolic reprogramming pathway instigated by epigenetic loss of the ATP synthase subunit ATP5H, which leads to ROS accumulation and HIF-1α stabilization under normoxia. Furthermore, this pathway confers to tumor cells a stem-like and invasive phenotype. In vivo delivery of antioxidants reverses these phenotypic changes and resensitizes tumor cells to therapy. ATP5H loss in the tumor is strongly linked to failure of therapy, disease progression, and poor survival in patients with cancer. Collectively, our results reveal a mechanism underlying immune-driven multimodality resistance to cancer therapy and demonstrate that rational targeting of mitochondrial metabolic reprogramming in tumor cells may overcome this resistance. We believe these results hold important implications for the clinical management of cancer.

Original languageEnglish
Pages (from-to)4098-4114
Number of pages17
JournalJournal of Clinical Investigation
Volume128
Issue number9
DOIs
Publication statusPublished - 2018 Aug 31

Fingerprint

Neoplasms
Therapeutics
Immune System
Neoplastic Stem Cells
Cytotoxic T-Lymphocytes
Cell- and Tissue-Based Therapy
Metabolic Networks and Pathways
Epigenomics
Immunotherapy
Disease Progression
Radiotherapy
Antioxidants
Adenosine Triphosphate
Phenotype
Drug Therapy
Survival

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Song, Kwon Ho ; Kim, Jae Hoon ; Lee, Young Ho ; Bae, Hyun Cheol ; Lee, Hyo Jung ; Woo, Seon Rang ; Oh, Se Jin ; Lee, Kyung Mi ; Yee, Cassian ; Kim, Bo Wook ; Cho, Hanbyoul ; Chung, Eun Joo ; Chung, Joon Yong ; Hewitt, Stephen M. ; Chung, Tae Wook ; Ha, Ki Tae ; Bae, Young Ki ; Mao, Chih Ping ; Yang, Andrew ; Wu, T. C. ; Kim, Tae Woo. / Mitochondrial reprogramming via ATP5H loss promotes multimodal cancer therapy resistance. In: Journal of Clinical Investigation. 2018 ; Vol. 128, No. 9. pp. 4098-4114.
@article{1dfeb46626534e9c929c35f8b47bfe37,
title = "Mitochondrial reprogramming via ATP5H loss promotes multimodal cancer therapy resistance",
abstract = "The host immune system plays a pivotal role in the emergence of tumor cells that are refractory to multiple clinical interventions including immunotherapy, chemotherapy, and radiotherapy. Here, we examined the molecular mechanisms by which the immune system triggers cross-resistance to these interventions. By examining the biological changes in murine and tumor cells subjected to sequential rounds of in vitro or in vivo immune selection via cognate cytotoxic T lymphocytes, we found that multimodality resistance arises through a core metabolic reprogramming pathway instigated by epigenetic loss of the ATP synthase subunit ATP5H, which leads to ROS accumulation and HIF-1α stabilization under normoxia. Furthermore, this pathway confers to tumor cells a stem-like and invasive phenotype. In vivo delivery of antioxidants reverses these phenotypic changes and resensitizes tumor cells to therapy. ATP5H loss in the tumor is strongly linked to failure of therapy, disease progression, and poor survival in patients with cancer. Collectively, our results reveal a mechanism underlying immune-driven multimodality resistance to cancer therapy and demonstrate that rational targeting of mitochondrial metabolic reprogramming in tumor cells may overcome this resistance. We believe these results hold important implications for the clinical management of cancer.",
author = "Song, {Kwon Ho} and Kim, {Jae Hoon} and Lee, {Young Ho} and Bae, {Hyun Cheol} and Lee, {Hyo Jung} and Woo, {Seon Rang} and Oh, {Se Jin} and Lee, {Kyung Mi} and Cassian Yee and Kim, {Bo Wook} and Hanbyoul Cho and Chung, {Eun Joo} and Chung, {Joon Yong} and Hewitt, {Stephen M.} and Chung, {Tae Wook} and Ha, {Ki Tae} and Bae, {Young Ki} and Mao, {Chih Ping} and Andrew Yang and Wu, {T. C.} and Kim, {Tae Woo}",
year = "2018",
month = "8",
day = "31",
doi = "10.1172/JCI96804",
language = "English",
volume = "128",
pages = "4098--4114",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "9",

}

Song, KH, Kim, JH, Lee, YH, Bae, HC, Lee, HJ, Woo, SR, Oh, SJ, Lee, KM, Yee, C, Kim, BW, Cho, H, Chung, EJ, Chung, JY, Hewitt, SM, Chung, TW, Ha, KT, Bae, YK, Mao, CP, Yang, A, Wu, TC & Kim, TW 2018, 'Mitochondrial reprogramming via ATP5H loss promotes multimodal cancer therapy resistance', Journal of Clinical Investigation, vol. 128, no. 9, pp. 4098-4114. https://doi.org/10.1172/JCI96804

Mitochondrial reprogramming via ATP5H loss promotes multimodal cancer therapy resistance. / Song, Kwon Ho; Kim, Jae Hoon; Lee, Young Ho; Bae, Hyun Cheol; Lee, Hyo Jung; Woo, Seon Rang; Oh, Se Jin; Lee, Kyung Mi; Yee, Cassian; Kim, Bo Wook; Cho, Hanbyoul; Chung, Eun Joo; Chung, Joon Yong; Hewitt, Stephen M.; Chung, Tae Wook; Ha, Ki Tae; Bae, Young Ki; Mao, Chih Ping; Yang, Andrew; Wu, T. C.; Kim, Tae Woo.

In: Journal of Clinical Investigation, Vol. 128, No. 9, 31.08.2018, p. 4098-4114.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Mitochondrial reprogramming via ATP5H loss promotes multimodal cancer therapy resistance

AU - Song, Kwon Ho

AU - Kim, Jae Hoon

AU - Lee, Young Ho

AU - Bae, Hyun Cheol

AU - Lee, Hyo Jung

AU - Woo, Seon Rang

AU - Oh, Se Jin

AU - Lee, Kyung Mi

AU - Yee, Cassian

AU - Kim, Bo Wook

AU - Cho, Hanbyoul

AU - Chung, Eun Joo

AU - Chung, Joon Yong

AU - Hewitt, Stephen M.

AU - Chung, Tae Wook

AU - Ha, Ki Tae

AU - Bae, Young Ki

AU - Mao, Chih Ping

AU - Yang, Andrew

AU - Wu, T. C.

AU - Kim, Tae Woo

PY - 2018/8/31

Y1 - 2018/8/31

N2 - The host immune system plays a pivotal role in the emergence of tumor cells that are refractory to multiple clinical interventions including immunotherapy, chemotherapy, and radiotherapy. Here, we examined the molecular mechanisms by which the immune system triggers cross-resistance to these interventions. By examining the biological changes in murine and tumor cells subjected to sequential rounds of in vitro or in vivo immune selection via cognate cytotoxic T lymphocytes, we found that multimodality resistance arises through a core metabolic reprogramming pathway instigated by epigenetic loss of the ATP synthase subunit ATP5H, which leads to ROS accumulation and HIF-1α stabilization under normoxia. Furthermore, this pathway confers to tumor cells a stem-like and invasive phenotype. In vivo delivery of antioxidants reverses these phenotypic changes and resensitizes tumor cells to therapy. ATP5H loss in the tumor is strongly linked to failure of therapy, disease progression, and poor survival in patients with cancer. Collectively, our results reveal a mechanism underlying immune-driven multimodality resistance to cancer therapy and demonstrate that rational targeting of mitochondrial metabolic reprogramming in tumor cells may overcome this resistance. We believe these results hold important implications for the clinical management of cancer.

AB - The host immune system plays a pivotal role in the emergence of tumor cells that are refractory to multiple clinical interventions including immunotherapy, chemotherapy, and radiotherapy. Here, we examined the molecular mechanisms by which the immune system triggers cross-resistance to these interventions. By examining the biological changes in murine and tumor cells subjected to sequential rounds of in vitro or in vivo immune selection via cognate cytotoxic T lymphocytes, we found that multimodality resistance arises through a core metabolic reprogramming pathway instigated by epigenetic loss of the ATP synthase subunit ATP5H, which leads to ROS accumulation and HIF-1α stabilization under normoxia. Furthermore, this pathway confers to tumor cells a stem-like and invasive phenotype. In vivo delivery of antioxidants reverses these phenotypic changes and resensitizes tumor cells to therapy. ATP5H loss in the tumor is strongly linked to failure of therapy, disease progression, and poor survival in patients with cancer. Collectively, our results reveal a mechanism underlying immune-driven multimodality resistance to cancer therapy and demonstrate that rational targeting of mitochondrial metabolic reprogramming in tumor cells may overcome this resistance. We believe these results hold important implications for the clinical management of cancer.

UR - http://www.scopus.com/inward/record.url?scp=85052579979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052579979&partnerID=8YFLogxK

U2 - 10.1172/JCI96804

DO - 10.1172/JCI96804

M3 - Article

C2 - 30124467

AN - SCOPUS:85052579979

VL - 128

SP - 4098

EP - 4114

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 9

ER -